Dose-intense paclitaxel, etoposide and cyclophosphamide: A safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer

Bone Marrow Transplantation

Volumn 25, Issue 2, 2000, Pages 123-130

  Bilgrami, S ^a   Feingold, J M ^a   Bona, R D ^a   Edwards, R L ^a   Khan, A M ^a   Rodriguez Pinero, F ^a   Khan, I A ^a   Kazierad, D ^a   Clive, J ^a   Tutschka, P J ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Breast cancer; Cyclophosphamide; Etoposide; Paclitaxel; Stem cell mobilization; Tumor cytoreduction

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ALKALOID; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL;

ADULT; ALOPECIA; ARTICLE; BREAST METASTASIS; DIARRHEA; DRUG TOLERABILITY; FEVER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; STEM CELL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 17444446878     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702125     Document Type: Article

References (38)

1. Bezwodu WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
2. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Phase III randomized trial of high dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the Philadelphia Intergroup Study (PBT-1). Proc Am Soc Clin Oncol 1999; 18: 1a.
3. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
4. Siena S, Bregni M, Belli N et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
5. Gregory CJ, Eaves AC. Human marrow cells capable of erythropoietic differentiation in vitro: definition of three eythroid colony responses, Blood 1977; 49: 855-864.
6. Miller AB, Hoogstraten B, Staguet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
7. McCredie K, Hersh E, Friereich E. Cells capable of colony formation in the peripheral blood of man. Science 1971; 171: 293-294.
8. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-1039.
9. To LB, Haylock DN, Kimber RJ, Juttner CA. High levels of circulating hemopoietic stem cells in very early remission from acute non-lymphoblastic leukemia and their collection and preservation. Br J Haematol 1984; 58: 399-410.
10. Henon PR, Butturini A, Gale RP. Blood-derived hematopoietic cell transplants: blood to blood? Lancet 1991; 337: 961-963.
11. Lowry PA, Tabbara IA. Peripheral hematopoietic stem cell transplantation: current concepts. Exp Hematol 1992; 20: 937-942.
12. Gillespie TW, Hillyer CD. Peripheral blood progenitor cells for marrow reconstitution: mobilization and collection strategies. Transfusion 1996; 36: 611-624.
13. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-2258.
14. Moog R, Muller N. Technical aspects and performance in collecting peripheral blood progenitor cells. Ann Hematol 1998; 77: 143-147.
15. Siena S, Bregni M, Brando M et al. Circulating CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905-1914.
16. To LB, Shepperd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442-447.
17. Tarella C, Ferrero D, Bregni M et al. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer 1991; 27: 22-27.
18. Demirer T, Buckner CD, Storer B et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 1997; 15: 684-690.
19. Demirer T, Rowley S, Buckner CD et al. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 1995; 13: 1714-1719.
20. Socinski MA, Cannistra SA, Elias A et al. Granulocyte-macrophage colony stimulating factor expands the circulating hemopoietic progenitor cell compartment in man. Lancet 1988; I: 1194-1198.
21. Haas R, Ho AD, Bredthauer U et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony stimulating factor. Exp Hematol 1990; 18: 94-98.
22. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
23. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
24. Rosenfeld CS, Shadduck PK, Zeigler ZR et al. Cyclophosphamide mobilized peripheral blood stem cells in patients with lymphoid malignancies. Bone Marrow Transplant 1995; 15: 433-438.
25. Brugger W, Bross K, Frisch J et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 1992; 79: 1193-1200.
26. Schneider JG, Crown JP, Wasserheit C et al. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients. Bone Marrow Transplant 1994; 14: 877-884.
27. Schimazaki C, Oku N, Ashihara E et al. Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recominant human grunulocyte-colony stimulating factor. Bone Marrow Transplant 1992; 10: 341-346.
28. Menichella G, Pierelli L, Scambia G et al. Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer. Bone Marrow Transplant 1994; 14: 907-912.
29. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients. Transfusion 1997; 37: 896-903.
30. Schwartzberg LS, Weaver CH, Birch R et al. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer. J Hematother 1998; 7: 141-150.
31. Steward DA, Guo D, Morris D et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant 1999; 23: 111-117.
32. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheralblood stem cells. J Clin Oncol 1995; 13: 2547-2555.
33. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloblative chemotherapy. Blood 1995; 86: 3961-3969.
34. Olivieri A, Offidani M, Ciniero L et al. Optimization of the yield of PBSC for autotransplantation mobilized by high-dose chemotherapy and G-CSF: proposal for a mathematical model. Bone Marrow Transplant 1994; 14: 273-278.
35. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
36. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-3044.
37. Kohno A, Takeyama K, Narabayashi M et al. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor. Bone Marrow Transplant 1995; 15: 49-54.
38. Harris JR, Morrow M, Norton L. Malignant tumors of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer. Principles and Practice of Oncology. Lippincott-Raven: Philadelphia, 1997, pp 1557-1616.